Objectives: The recurrence rate of benign endometrial polyps after a hysteroscopic polypectomy is low, between 0% and 15%. There are limited follow-up duration data on recurrence factors for benign polyps after hysteroscopic polypectomy, including recurrences with Versapoint® versus resectoscope. This study aims to estimate the rate of symptomatic recurrence following hysteroscopic polypectomy and to analyze the possible risk factors involved with Versapoint® versus resectoscope. Materials and Methods: We designed a retrospective cohort study in a tertiary university hospital in Seville (Spain) which looked at the results of polypectomy with a 9-mm resectoscope on 42 women between 2008 and 2015 compared to 151 women using Versapoint® during 2014. Results: The rate of first recurrence was 24.35%. There was a strong positive correlation between the recurrence and the follow-up duration (odds ratio [OR] = 2.58; 95% confidence interval [CI] = 1.68–5.04; P = 0.000), the polyps causing abnormal uterine bleeding (OR = 2.5; 95% CI: 1.1–3; P = 0.04), and a polyp size >15 mm (OR = 1.63; 95% CI = 1.3–3.1; P = 0.02). There were no statistical differences in polyps' recurrence among the types of hysteroscopic polypectomy ( P > 0.05). Conclusion: The main risk factors for recurrence were polyps causing abnormal uterine bleeding, size, and follow-up duration.

Objective: High-grade squamous intraepithelial lesions (HSIL) are the precursors of invasive cervical carcinomas and are generally associated with the integration of mucosotropic human papillomavirus (HPV) DNA into the host cell genome. Detection of HPV is easy to perform nowadays, even in laboratories with limited technological capacity, and follow-up procedures for patients with HSIL are well established. Study Design: HPV detection was performed in a large group of patients with HSIL, and results were correlated with cytological, histological, and colposcopic findings. Discrepancies were examined and discussed. Results: Conventional Papanicolaou (Pap) screening detected 446 HSIL (0.20%) in 218,906 cervical smears. HPV detection by PCR was positive in 339/358 (94.7%) patients. The strains involved were: HPV 16 in 180 patients (53.1%), HPV 18 in 35 (10.3%), HPV 31/33 in 27 (8%), HPV 6/11 in 10 (2.96%), and an unidentified type in 73 (30%). For the last 97 patients (2006–2007), HPV typing was expanded with the following results: HPV 52 was detected in 9 patients (9.2%), HPV 58 in 6 (6.1%), HPV 51 in 4 (4.1%), HPV 68 in 2 (2.0%), and HPV 39 in 1 (1.0%). The number of nonidentified patients dropped to 9 (9.4%); in addition, 14/97 (14.4%) patients were infected with 2 or more viral types. Finally, 19 (5.3%) patients were HPV negative. Colposcopy revealed minor changes in 59 patients (17.3%), major changes in 264 (77.6%), and normal findings in 17 (5.1%). A biopsy was taken in 331/446 patients, and the diagnosis of HSIL or overt malignancy was histologically confirmed in 281 (84.9%) patients: CIN II in 46, CIN III in 224, and histologically upgraded in 11 (6 microinvasive squamous carcinomas, 1 squamous carcinoma, 2 in situ endocervical adenocarcinomas, and 2 microinvasive endocervical adenocarcinomas). Thirty-five patients (10.6%) were downgraded to CIN I and 15 (4.5%) patients had a negative biopsy. Follow-up in the negative-biopsy patients confirmed the existence of SIL in 11 patients [1 HSIL and 10 low-grade squamous intraepithelial lesions (LSIL)] while 4 were considered false positives (atrophic changes, 2; reactive changes, 2). After treatment, 31/331 (9.36%) patients displayed recurrence (HSIL in 29 and LSIL in 2). The viral strains involved in patients with recurrence were HPV 16 in 16 patients (51.6%); HPV 18 in 4 (12.9%); HPV 16 and 18 in 1 (3.2%); HPV 31 in 1 (3.2%); HPV 52 in 1 (3.2%); HPV 18, 31, and 58 in 1 (3.2%); HPV 68 in 1 (3.2%); HPV 51 and 73 in 1 (3.2%), and an unidentified type in 5 (16.1%). Follow-up in 14/19 HSIL and HPV-negative patients confirmed the existence of cervical pathology. Conclusions: HPV detection improves diagnostic sensitivity and provides an ideal tool for monitoring the response to treatment in HSIL patients. The pathogenic relevance of HPV strain 18 may be greater than previously assumed.

No abstract

No abstract

Recibido el 17 de junio de 2012; aceptado el 24 de julio de 2012 Disponible en Internet el 5 de enero de 2013 PALABRAS CLAVE Entrada laparoscópica; Trocar; Aguja de VersesResumen Objetivo: Comparar la entrada directa umbilical con trocar sin neumoperitoneo previo en laparoscopia con el uso de la aguja de Veress.Método: Se revisan las hojas quirúrgicas de 183 pacientes en las que se usó la vía laparoscópica, dividiéndolas en 2 grupos: G1: usando la aguja de Veress, y G2: usando la entrada umbilical del trocar sin neumoperitoneo previo. Se recogieron las complicaciones producidas.Resultados: La edad media era de 40 años y el IMC medio de 29. Solo se registraron 3 casos de enfisema preperitoneal y en todos ellos se usó la aguja de Veress.Conclusión: Según nuestra experiencia, y en concordancia con la literatura, el método de entrada directa umbilical del trocar sin neumoperitoneo previo es un método seguro, sin complicaciones en nuestra serie, presentando ventajas: mayor velocidad de consecución del neumoperitoneo, ausencia de riesgo de embolismo gaseoso, simplificación de los pasos quirúr-gicos y menor tasa de fallos en la entrada. ß 2012 SEGO. Publicado por Elsevier España, S.L. Todos los derechos reservados. KEYWORDS Laparoscopic entry; Trocar; Veress needleTransumbilical direct trocar entry without prior pneumoperitoneum: A safe alternative Abstract Objective: To compare transumbilical direct trocar entry without prior pneumoperitoneum in laparoscopic surgery with Veress needle insertion. Method:The surgical records of 183 patients who underwent laparoscopy were reviewed. The patients were divided into two groups according to the surgical technique employed: group 1: Veress needle insertion; group 2, transumbilical direct trocar entry without prior pneumoperitoneum. The complications were recorded.